The Evaluation of Two Measures of Quality of Life in Patients With Type I and Type II Diabetes

Jacobson, Alan M.; Groot, Mary de; Samson, Jacky

doi:10.2337/diacare.17.4.267

Cited by 435 publications

(369 citation statements)

References 0 publications

Supporting

Mentioning

307

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with other studies that have demonstrated lower health-utility scores in women with diabetes [6,[31][32][33] and worse QoL in the presence of complications [6,20,33,34]. However, even with inclusion of gender and diabetic complications in the model, frequency of hyperglycemic symptoms was associated with lower health-utility scores.…”

Section: Discussionsupporting

confidence: 92%

Glycemia and the Quality of Well-Being in Patients with Diabetes

et al. 2004

View full text Add to dashboard Cite

Objectives: To investigate the cross-sectional relationships among self-reported frequencies of symptomatic hyperglycemia and hypoglycemia, HbA1c, and symptoms in the Quality of Well-Being Self-Administered (QWB-SA), and to examine the associations among these measures of glycemia and health-utility scores. Methods: The study group included 1522 patients with diabetes who attended University of Michigan Health System clinics. Published studies were reviewed to identify symptoms in the QWB-SA that might be associated with measures of glycemia. Linear-regression analyses were performed to evaluate the strength of the associations among the frequency of self-reported measures of glycemia, QWB-SA symptoms, and QWB-SA-derived health-utility scores. Results: Frequency of hyperglycemic symptoms was associated with 3% of the variance in the QWB-SA-derived health-utility score in type-1 diabetes and with 5% of the variance in type-2 diabetes. Frequency of hypoglycemic symptoms was not associated with the QWB-SAderived health-utility score in type-1 diabetes but was associated with 1% of the variance in type-2 diabetes. HbA1c levels were not significantly associated with QWB-SA-derived health-utility scores. After controlling for age, gender, and complications, frequency of hyperglycemic symptoms was significantly associated with QWB-SA-derived health-utility scores in type-1 and type-2 diabetes. Conclusions: Reported frequency of hyperglycemic symptoms is associated with symptoms included in the QWB-SA and with QWB-SAderived health-utility scores. The QWB-SA may be an appropriate measure to assess the health burden of hyperglycemia.

show abstract

Section: Discussionsupporting

confidence: 92%

Glycemia and the Quality of Well-Being in Patients with Diabetes

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The better the acceptance of the disease, the more effective the patient's performance, not only in relation to accession to control of blood glucose. [22][23][24][25] Groups that present low acceptance of the disease also present inadequate control of blood glucose. The level of acceptance of the patient with diabetes and situations related to their routine have a direct influence on blood glucose levels and adherence to treatment.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of information retention and adherence to treatment in patients with gestational diabetes mellitus after multidisciplinary group

Sousa

Fiuza

Mikami

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Objective:To evaluate the retention of information after participation in multidisciplinary group in patients with gestational diabetes mellitus (GDM) through a phone contact. Method: 122 pregnant women diagnosed with gestational diabetes were included. After diagnosis of gestational diabetes, the patients were referred to the multidisciplinary group where they received medical, nutrition and nursing guidelines related to the disease. After three days these patients received one telephone call from a nurse, who made the same questions regarding the information received. In the statistical analysis, results were presented as absolute and relative frequencies. Results: Most patients 119/122 patients (97.5%) were managing to do self glucose monitoring. Twenty-one patients (17.2%) reported having difficulty performing the blood glucose, especially finger pricking. When questioning whether the woman was following the proposed diet, 24/122 (19.7%) patients said they did not; the meal frequency was not reached by 23/122 (18.9%) of the women, and forty-seven (38.5%) of the women reported having ingested sugar in the days following the guidance in multidisciplinary group. Conclusion: Regarding the proposed treatment, there was good adherence of patients, especially in relation to blood glucose monitoring. As for nutritional control, we observed greater difficulty in following the guidelines demonstrating the need for long-term monitoring, as well as further clarification to the patients about the importance of nutrition in diabetes management.

show abstract

“…However, diabetic complications (especially macrovascular diseases) and other comorbid illnesses seem to deteriorate HRQL measured by SF-36 among type II diabetes patients. [12][13][14][15][16][17] One randomised intervention study showed that regular phone contacts with the patients improved glycaemic control but did not induce any improvement in HRQL measured by SF-36. 36 Another study showed that by achieving good glycaemic control (HbA1c from 10.4 to 7.8% during 1 y follow-up) and by losing hyperglycaemic symptoms, the patients gained HRQL benefits especially in PF, vitality, and HC since last year.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] Weight loss achieved by surgical techniques 1 and lifestyle interventions [4][5][6][7][8][9][10][11] has improved HRQL. Diabetes with its complications has been associated with deteriorated HRQL [12][13][14][15][16] and improvement in glycaemic control with the loss of hyperglycaemic symptoms has improved HRQL in type II diabetes patients. 17 Sibutramine, a norepinephrine and serotonin reuptake inhibitor enhances satiety 18,19 and results in sustained weight loss in obese patients.…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

2004

View full text Add to dashboard Cite

OBJECTIVE:We evaluated the effects of 12-month treatment with sibutramine 15 mg daily compared with placebo on healthrelated quality of life (HRQL) in obese type II diabetes patients. We examined the associations between the changes in HRQL and in weight, glycaemic control, and haemodynamic variables. We also explored the predictive value of HRQL and its changes early during treatment. DESIGN: A randomised clinical trial. The subjects were enrolled in a 2-week single-blind run-in period with a modestly hypocaloric diet (700 kcal daily deficit) and then randomised to receive either sibutramine 15 mg (n ¼ 114, 60% female) or placebo (n ¼ 122, 58% female) once daily with the hypocaloric diet for 12 months. SUBJECTS: Obese (mean BMI 36 kg/m 2 and age 54 y) type II diabetes patients untreated with antidiabetic medications. MEASUREMENTS: The main outcome measures included body weight and HRQL (the RAND 36-Item Health Survey 1.0). RESULTS: The mean weight loss was greater in the sibutramine group (À7.1 kg) than in the placebo group (À2.6 kg, Po0.001). The baseline HRQL was relatively high. There were no significant differences between the treatment groups in glycaemic control or in any of the RAND-36 scales during the study. The scores on physical functioning (PF) and health change (HC) since last year improved in both groups and this improvement was related to weight loss. When HRQL changes were examined in categories of weight loss, the scores on PF and HC increased with Z5% weight loss, but the scores on vitality (V) and general health (GH) increased only after Z15% weight loss. Decrease in HbA1c was associated with increases in the scores of PF, GH, V, mental health, and HC. In the sibutramine group, the increase in diastolic blood pressure was associated with the decrease in the scores of PF, physical role functioning, emotional role functioning (ERF), social functioning (SF), and bodily pain. High baseline scores on ERF and SF, and low scores on V predicted weight loss at 12 months. Also, increasing scores on PF and V during the first 3 months predicted weight loss at 12 months. The sum of four dichotomised HRQL variables (baseline ERF Z75 ¼ 1 and o75 ¼ 0; baseline SFZ80 ¼ 1 and o80 ¼ 0; 3-month change in PF40 ¼ 1 and r0 ¼ 0; 3-month change in V40 ¼ 1 and r0 ¼ 0) predicted weight loss: In the group with sum 0, the mean(s.d.) weight change at 12 months was 0.0(2.6)% and with sum 4 it was -9.0(8.1)% of baseline weight. CONCLUSION: Despite the superior weight loss, sibutramine 15 mg daily did not produce HRQL benefits over placebo when measured with the generic RAND-36 in obese type II diabetes patients. PF and HC since last year improved with Z5% weight loss, but Z15% weight loss was needed to achieve a cluster of HRQL improvements. The decrease in HbA1c was associated with many HRQL benefits. Poor baseline HRQL and the improvement observed in the first months of treatment may prove to be useful in predicting success in long-term weight loss.

show abstract

The Evaluation of Two Measures of Quality of Life in Patients With Type I and Type II Diabetes

Cited by 435 publications

References 0 publications

Glycemia and the Quality of Well-Being in Patients with Diabetes

Glycemia and the Quality of Well-Being in Patients with Diabetes

Evaluation of information retention and adherence to treatment in patients with gestational diabetes mellitus after multidisciplinary group

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

Contact Info

Product

Resources

About